id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-028945-p3hhd5ed	Şahar, Esra Atalay	Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis	2020-07-10		.txt	text/plain	7383	433	55	Thereafter, we developed a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and administered to a murine model to determine its immunogenicity and protection efficiency against lethal toxoplasmosis. Hexavalent recombinant protein mixture (+) Montanide ISA 50 V vaccine induced significantly high levels of IgG1 and IgG2a at day 42 compared to the controls groups (P < 0.001, **). Overall, in mice administered with Hexavalent recombinant protein mixture (+) Montanide ISA 50 V, IgG2a and IgG1 levels showed a strong and balanced immune response. Overall, the Th1 part of the immune response elicited by hexavalent recombinant protein mixture (+) Montanide ISA 50 V induced significant levels of CD4 + and CD8 + T lymphocytes secreting IFN-γ and conferred significant protection in Swiss Outbred mice challenged with lethal dose of T.	./cache/cord-028945-p3hhd5ed.txt	./txt/cord-028945-p3hhd5ed.txt